Phenylephrine HCI Injection

Available Dosage Strengths

1 mg/mL

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Description

Phenylephrine is an alpha-1 adrenergic receptor agonist used in various clinical settings to induce vasoconstriction. In the management of prolonged erection greater than 4 hours (priapism), phenylephrine 0.1% (1 mg/mL) solution is administered via intracavernous injection to achieve detumescence by contracting smooth muscle in the corpora cavernosa and reducing blood flow.^1-4

Mechanism of Action

Phenylephrine acts as a selective alpha-1 adrenergic receptor agonist. When injected directly into the corpus cavernosum, it causes vasoconstriction of the cavernous arterial smooth muscle, leading to decreased arterial inflow and increased venous outflow. This action facilitates resolution of the prolonged erection that can be induced from oral or intracavernousal medications used for the treatment of erectile dysfunction (sildenafil, tadalafil, alprostadil, phentolamine, papaverine, vardenafil etc..)^1-4

Adverse Reactions

Common^1-4

Local: 

Pain at the injection site
Penile fibrosis (scarring)
Hematoma or ecchymosis

Systemic (especially with higher doses or improper administration): 

Hypertension
Reflex bradycardia
Arrhythmias
Headache
Anxiety or nervousness

Contraindications & Precautions

Contraindications: ^1-4

Known hypersensitivity to phenylephrine or any component of the formulation
Severe hypertension or cardiovascular disease (relative contraindication)

Precautions: ^1-4

Monitor blood pressure and heart rate during and after administration
Use the lowest effective dose and shortest duration to minimize systemic effects
Avoid in patients with significant cardiovascular comorbidities unless necessary and under close supervision
Use caution in renally impaired patients

Storage

20°C to 25°C (68°F to 77°F) in a dry place, away from heat and light. Do not refrigerate. Do not freeze. Keep out of reach of children.

References

Clinical Pharmacology powered by Elsevier (ClinicalKey) – Phenylephrine Monograph. Accessed June 22 2025 ; https://www.clinicalkey.com 
Montague DK, et al. “American Urological Association guideline on the management of priapism.” J Urol. 2003;170(4):1318-1324. Accessed June 22 2025 ; https://www.auanet.org/documents/Guidelines/PDF/Priapism-JU.pdf 
Broderick GA, et al. “Priapism: Pathogenesis, epidemiology, and management.” J Sex Med. 2010;7(1 Pt 2):476–500. Accessed June 22 2025 ; https://pubmed.ncbi.nlm.nih.gov/20092449/ 
Burnett AL. “Priapism: current principles and practice.” Urol Clin North Am. 2007;34(4):631–642. Accessed June 22 2025; https://pubmed.ncbi.nlm.nih.gov/17983902

Disclaimer

This information is for educational purposes only. This compounded product has not been reviewed, approved, or evaluated by the Food and Drug Administration for safety and effectiveness. This product is not intended to diagnose, treat, cure, or prevent any disease. No claims are made regarding treatment, cure, or prevention of any disease or condition.

This information may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.